Hammersmith Hospital Joins AFFECT Trial to Improve Heart Valve Care

Hammersmith Hospital has joined a national clinical research initiative to determine the most effective blood-thinning treatment for patients recovering from mitral valve repair surgery. The AFFECT trial seeks to compare traditional vitamin K antagonists against newer direct oral anticoagulants (DOACs) to reduce the risk of stroke and other postoperative complications in patients with coexisting heart rhythm issues.

Key Clinical Takeaways:

• The AFFECT trial aims to recruit 1,282 participants across the UK to establish the optimal standard of care for patients with both mitral regurgitation and atrial fibrillation.
• The study directly compares the safety and efficacy of vitamin K antagonists (such as warfarin) against newer Direct Oral Anticoagulants (DOACs).
• Patients will undergo monitoring for at least 12 months, with follow-up assessments continuing for up to four years to evaluate long-term outcomes, including stroke prevention and cost-effectiveness.

Mitral Valve Failure Increases Stroke Risk After Surgery

Mitral regurgitation occurs when the mitral valve fails to seal properly, forcing the heart to pump blood backward into the left atrium. This mechanical failure increases the workload on the heart, often leading to chronic fatigue, breathlessness, and potential heart failure. For the thousands of patients undergoing surgical repair for this condition annually in the UK, the presence of an accompanying heart rhythm disturbance—such as atrial fibrillation—complicates the recovery phase. These individuals require anticoagulation therapy to mitigate the elevated risk of stroke and thromboembolic events following the procedure.

Evaluating Treatment Protocols in the AFFECT Trial

Current clinical practice relies heavily on vitamin K antagonists, with warfarin remaining a standard treatment option. The AFFECT trial seeks to generate high-quality evidence comparing these traditional agents to DOACs, which are increasingly used in clinical settings. Researchers will randomize 1,282 participants to receive one of the two medication classes, with treatment initiation occurring before hospital discharge.

According to the National Institute for Health and Care Research (NIHR), which funds the study, this trial addresses a significant clinical gap. Professor Enoch Akowuah, the chief investigator for the trial at University Hospitals Tees, noted that while anticoagulation is essential for these patients, clinicians currently lack a clear consensus on which treatment offers the most favorable balance between safety and protection.

Clinical Research Infrastructure at Hammersmith Hospital

The study at Hammersmith Hospital is led by Mr. Emad AlJaaly, a cardiac and minimally invasive surgeon and the cardiothoracic research lead at Imperial College Healthcare NHS Trust. Hammersmith Hospital joins this national effort as one of London’s seven designated heart attack centres and a close collaborator with the National Heart and Lung Institute. Research activities at the Trust are supported by the NIHR Imperial Biomedical Research Centre, which received £95 million in 2022 to advance experimental treatments and diagnostic methodologies.

Clinical teams are responsible for identifying eligible patients for the AFFECT trial during routine consultations.

The trial’s results are expected to influence national treatment guidelines, potentially shifting the standard of care for thousands of cardiac patients. By focusing on long-term outcomes, including quality of life and healthcare resource utilization, the study aims to provide a reliable framework for clinicians to make evidence-based decisions for patients with complex valvular disease.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.